公开(公告)号：US10125137B2

公开(公告)日：2018-11-13

申请号：US15551015

申请日：2016-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  John F. Kadow

IPC: C07D487/04 ,  C07D405/10 ,  C07D471/04 ,  C07D487/10 ,  A61K45/06 ,  A61K31/4025 ,  A61K31/4162 ,  A61K31/4188 ,  A61K31/407 ,  A61K31/437

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV: Formula (I).

公开(公告)号：US20150329543A1

公开(公告)日：2015-11-19

申请号：US14725318

申请日：2015-05-29

Applicant: Bristol-Myers Squibb Company

Inventor： Tao Wang ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Abstract translation: 本发明提供具有药物和生物影响性质的化合物，其药物组合物和使用方法。 特别地，本发明涉及氮杂吲哚乙酰基哌嗪衍生物。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。

公开(公告)号：US20150322085A1

公开(公告)日：2015-11-12

申请号：US14762537

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  Zhongxing Zhang ,  Paul Michael Scola

IPC: C07D498/08 ,  A61K31/53 ,  A61K45/06 ,  C07D251/52

CPC classification number: A61K31/53 ,  A61K38/13 ,  A61K38/20 ,  A61K38/21 ,  A61K45/06 ,  C07D251/52 ,  C07D498/08 ,  A61K2300/00

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US08916702B2

公开(公告)日：2014-12-23

申请号：US13758624

申请日：2013-02-04

Applicant: Bristol-Myers Squibb Company

Inventor： Tao Wang ,  Paul Michael Scola ,  Zhongxing Zhang ,  Zhiwei Yin ,  Qian Zhao

IPC: C07D251/52 ,  A61K31/53 ,  A61P31/14 ,  C07D401/14 ,  C07D513/04 ,  C07D405/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D401/12

CPC classification number: C07D513/04 ,  C07D251/52 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US10125111B2

公开(公告)日：2018-11-13

申请号：US15551002

申请日：2016-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D307/82 ,  C07D307/84 ,  C07D405/04 ,  C07D405/12

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus, (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US10087167B2

公开(公告)日：2018-10-02

申请号：US15551012

申请日：2016-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  John F. Kadow

IPC: C07D405/10 ,  A61P31/14 ,  C07D405/12 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14 ,  C07D307/84

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and areuseful in treating those infected with HCV.

公开(公告)号：US20180030016A1

公开(公告)日：2018-02-01

申请号：US15551002

申请日：2016-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D307/82 ,  C07D405/12 ,  C07D405/04

CPC classification number: C07D307/82 ,  C07D307/84 ,  C07D405/04 ,  C07D405/12

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:

公开(公告)号：US20160075703A1

公开(公告)日：2016-03-17

申请号：US14878270

申请日：2015-10-08

Applicant: Bristol-Myers Squibb Company

Inventor： TAO WANG ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC: C07D471/04 ,  C07D491/048

CPC classification number: C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

公开(公告)号：US20150259342A1

公开(公告)日：2015-09-17

申请号：US14725298

申请日：2015-05-29

Applicant: Bristol-Myers Squibb Company

Inventor： Tao Wang ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC: C07D471/04 ,  C07D491/048

CPC classification number: C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Abstract translation: 本发明提供具有药物和生物影响性质的化合物，其药物组合物和使用方法。 特别地，本发明涉及具有式I的亚硝基二氧乙酰基哌嗪衍生物：其中Q是这些化合物具有独特的抗病毒活性，无论是单独使用还是与其它抗病毒剂，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。

公开(公告)号：US20150210676A1

公开(公告)日：2015-07-30

申请号：US14419568

申请日：2013-08-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Zhiwei Yin ,  John F. Kadow ,  Nicholas A. Meanwell

IPC: C07D413/12 ,  A61K45/06 ,  A61K31/5513 ,  C07D471/04 ,  A61K31/553 ,  C07D403/12

CPC classification number: C07D413/12 ,  A61K31/5513 ,  A61K31/553 ,  A61K45/06 ,  C07D403/12 ,  C07D471/04

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: (F) wherein A is selected from the group consisting of: (F) and; (F) and wherein Z is: (F) are useful as HIV attachment inhibitors.

Abstract translation: 式I化合物，包括其药学上可接受的盐：（F）其中A选自：（F）和 （F），其中Z是：（F）可用作HIV附着抑制剂。